Insider Transactions in Q2 2017 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q2 2017)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 20
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,800
-2.05%
|
$47,600
$17.36 P/Share
|
|
Apr 20
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,800
+2.01%
|
$2,800
$1.81 P/Share
|
|
Apr 20
2017
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
2,294
-0.19%
|
$38,998
$17.37 P/Share
|
|
Apr 20
2017
|
Rodger Novak President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,294
+0.19%
|
$2,294
$1.81 P/Share
|
|
Apr 19
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,240
-1.78%
|
$130,320
$18.04 P/Share
|
|
Apr 19
2017
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,258
-2.6%
|
$130,644
$18.04 P/Share
|
|
Apr 19
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,258
+4.89%
|
$7,258
$1.81 P/Share
|
|
Apr 19
2017
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
47,706
-1.91%
|
$858,708
$18.09 P/Share
|
|
Apr 19
2017
|
Rodger Novak President |
BUY
Exercise of conversion of derivative security
|
Direct |
47,706
+3.64%
|
$47,706
$1.81 P/Share
|